Keros Therapeutics (KROS)
NASDAQ:KROS
Want to see KROS full AI Analyst Report?
Top Page
Keros Therapeutics
(NASDAQ:KROS)
Select Model
Select Model
Rating:54Neutral
Price Target:
$12.00
▲(2.83% Upside)
Action:Reiterated
Date:05/14/26
Overall score is held back primarily by unstable financial performance (TTM revenue decline, renewed losses, and negative free cash flow) despite a low-leverage balance sheet. Technicals are mixed with near-term stabilization but a longer-term downtrend, valuation is weak due to negative earnings, and recent corporate events provide a modest positive offset via clinical and strategic progress.
Positive Factors
Low-leverage balance sheet
Keros’s very low leverage provides durable financial flexibility to fund clinical programs and absorb operating volatility. A conservative capital structure reduces default risk, supports fundraising on more favorable terms, and preserves optionality for licensing, partnerships, or targeted bolt-on investments.
Negative Factors
Negative operating and free cash flow
Sustained negative operating and free cash flow indicates the company is burning cash to fund R&D and operations. This trend can force recurring financing, dilute shareholders, or constrain the pace of trials if capital markets tighten, placing long-term pressure on program continuity.
Read all positive and negative factors
Positive Factors
Negative Factors
Low-leverage balance sheet
Keros’s very low leverage provides durable financial flexibility to fund clinical programs and absorb operating volatility. A conservative capital structure reduces default risk, supports fundraising on more favorable terms, and preserves optionality for licensing, partnerships, or targeted bolt-on investments.
Read all positive factors
Keros Therapeutics (KROS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$207.81M
Dividend YieldN/A
Average Volume (3M)491.06K
Price to Earnings (P/E)―
Beta (1Y)0.95
Revenue Growth-84.55%
EPS Growth-1998.74%
CountryUS
Employees163
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.44
Shares Outstanding19,791,838
10 Day Avg. Volume348,824
30 Day Avg. Volume491,060
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)2.50
Price to Sales (P/S)3.11
P/FCF Ratio7.15
Enterprise Value/Market Cap0.34
Enterprise Value/Revenue2.13
Enterprise Value/Gross Profit2.21
Enterprise Value/Ebitda-0.74
Forecast
1Y Price Target
$21.20Price Target Upside81.66% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
EPS Forecast (FY)-4.82
Revenue Forecast (FY)$3.57M
Keros Therapeutics Business Overview & Revenue Model
Company Description
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical ...
How the Company Makes Money
Keros Therapeutics makes money primarily through collaboration and license arrangements rather than recurring sales of approved products. Its revenue has historically been driven by payments received from strategic partnerships, which can include ...
Keros Therapeutics Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
72
Positive
Cash Flow
48
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 33.18M | 244.06M | 3.55M | 151.00K | 0.00 | 20.10M |
| Gross Profit | 32.01M | 242.55M | 3.55M | 151.00K | 0.00 | 20.10M |
| EBITDA | -95.20M | 72.13M | -185.82M | -152.18M | -104.00M | -56.35M |
| Net Income | -85.14M | 87.01M | -187.35M | -152.99M | -104.68M | -58.74M |
Balance Sheet | ||||||
| Total Assets | 312.29M | 338.02M | 615.89M | 370.02M | 306.78M | 255.25M |
| Cash, Cash Equivalents and Short-Term Investments | 281.50M | 287.42M | 559.93M | 331.15M | 279.05M | 230.04M |
| Total Debt | 16.31M | 16.88M | 18.86M | 14.44M | 13.27M | 1.09M |
| Total Liabilities | 26.66M | 34.89M | 44.33M | 37.81M | 29.36M | 12.08M |
| Stockholders Equity | 285.63M | 303.13M | 571.55M | 332.21M | 277.42M | 243.17M |
Cash Flow | ||||||
| Free Cash Flow | -58.25M | 105.95M | -162.80M | -126.97M | -71.30M | -63.17M |
| Operating Cash Flow | -57.20M | 107.50M | -160.87M | -124.51M | -70.06M | -62.15M |
| Investing Cash Flow | -1.06M | -1.55M | -1.93M | -2.46M | -1.24M | -1.02M |
| Financing Cash Flow | -380.79M | -378.47M | 391.82M | 178.96M | 120.31M | 28.55M |
Keros Therapeutics Technical Analysis
Neutral
11.67
Price Trends
13.11
Negative
16.23
Negative
15.69
Negative
Market Momentum
-0.31
Negative
45.68
Neutral
49.30
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For KROS, the sentiment is Neutral. The current price of 11.67 is above the 20-day moving average (MA) of 11.49, below the 50-day MA of 13.11, and below the 200-day MA of 15.69, indicating a neutral trend. The MACD of -0.31 indicates Negative momentum. The RSI at 45.68 is Neutral, neither overbought nor oversold. The STOCH value of 49.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for KROS.
Keros Therapeutics Risk Analysis
Keros Therapeutics disclosed 79 risk factors in its most recent earnings report. Keros Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Keros Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | $635.31M | -18.47 | -6.27% | ― | 16.30% | -182.23% | |
58 Neutral | $1.33B | -5.37 | -35.89% | ― | ― | -63.41% | |
56 Neutral | $1.42B | -47.34 | -1254.88% | ― | ― | -13.14% | |
54 Neutral | $207.81M | ― | -17.04% | ― | -84.55% | -1998.74% | |
52 Neutral | $1.64B | -25.86 | -56.87% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $1.64B | -5.04 | -64.21% | ― | 27.23% | -12.53% |
* Healthcare Sector Average
KROS
Keros Therapeutics
10.50
-3.60
-25.53%
GYRE
Gyre Therapeutics
6.55
-4.56
-41.04%
KALV
KalVista Pharmaceuticals
26.73
14.66
121.46%
PVLA
Palvella Therapeutics
114.24
91.68
406.38%
NRIX
Nurix Therapeutics
15.86
6.35
66.72%
BCAX
Bicara Therapeutics Inc.
20.23
5.02
33.00%
Keros Therapeutics Corporate Events
Business Operations and StrategyProduct-Related Announcements
Keros Therapeutics Advances Rinvatercept in ALS Collaboration
Positive
Mar 9, 2026
On March 9, 2026, Keros Therapeutics announced it has entered into an agreement with Massachusetts General Hospital to design a Phase 2 clinical trial of its lead drug candidate rinvatercept for amyotrophic lateral sclerosis within the Healey ALS ...
Business Operations and Strategy
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation
Positive
Mar 4, 2026
On March 4, 2026, Keros Therapeutics updated its corporate presentation for use in meetings with investors, analysts and other stakeholders, making it available on its website. The presentation outlines the company’s strategy to leverage TGF...
Executive/Board Changes
Keros Therapeutics Adds Veteran Finance Leader to Board
Positive
Feb 26, 2026
On February 24, 2026, Keros Therapeutics’ board appointed former Lyell Immunopharma CFO and veteran healthcare investment banker Charles Newton as a Class III director, effective March 9, 2026, with a term running through the 2026 annual mee...
Business Operations and Strategy
Keros Therapeutics CEO to Present at Multiple Conferences
Positive
Feb 18, 2026
On February 18, 2026, Keros Therapeutics announced that President and CEO Jasbir S. Seehra will represent the company at three major healthcare investor conferences in late February and early March 2026. He is scheduled for a corporate presentatio...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.